Inhibrx Biosciences, Inc. — Form 8-K Summary
Reporting date: September 28, 2026. The filing reports a Regulation FD disclosure; it does not provide quarterly or annual financial results.
Business context and disclosure
The company posted an updated corporate presentation to the Investors section of its website and attached it as Exhibit 99.1. It says the presentation may be used in communications with the investment community. The presentation’s contents are not included in the supplied filing text.
Financial metrics and changes
The filing text provides no revenue, profit, cash flow, margins, debt, liquidity, or other financial metrics, and no comparable-period results. It does not describe specific changes to the business or financial position.
Outlook, risks, and other matters
No guidance, outlook, contingencies, or specific risk updates are stated in the supplied text. The company says it undertakes no obligation to update, supplement, or amend the presentation. Item 7.01 and its exhibit are furnished, not deemed filed for purposes of Exchange Act Section 18, and are not incorporated by reference except by specific reference in another filing.
Key facts for investors to verify
- Review Exhibit 99.1 or the company’s website for the presentation’s substantive business, pipeline, outlook, and risk disclosures.
- Do not treat this 8-K as a financial-results filing; the supplied text contains no financial statements or financial metrics.